ERBB2 and lung carcinoma: Targeted therapy is also an important component of lung cancer treatment, and treatment regimens require testing for EGFR, ALK, ROS1, RET, MET, BRAF, NTRK, HER2, NRG1, FGFR1, and PIK3CA (Guo et al., 2019; Wei et al., 2023).